Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Heinz Ludwig, Thomas Melchardt, Johannes Andel, Eberhard Gunsilius, Siegfried Sormann, Axel Hinke, Bernd L. Hartmann, Klaus Podar, Wolfgang Willenbacher, Alexander Egle, Andreas Petzer, Niklas Zojer, Ewald Wöll, Reinhard Ruckser, Boris Bozic, Clemens A. Schmitt, Sigrid Machherndl-Spandl, Maria-Theresa Krauth, Martin Schreder, Hermine AgisChristoph Tinchon, Michael Fillitz, Richard Greil

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Konferenzbeitrag in Fachzeitschrift

Fingerprint

Untersuchen Sie die Forschungsthemen von „Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)“. Zusammen bilden sie einen einzigartigen Fingerprint.

Medicine and Dentistry

Immunology and Microbiology